Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTICOV
2022-501408-81-01Phase 2Authorised
- Sponsor
- Inserm
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing Remdesivir (Veklury) strategy, Nirmatrelvir/ritonavir (Paxlovid) strategy and Combination remdesivir + nirmatrelvir/ritonavir strategy (3 arms). Primary endpoint: SARS-CoV-2 viral load <32 CT at Day 10. Planned start Jul 2023; status: authorised.
02
Drugs
remdesivirNirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-501408-81-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501408-81-01.